Adding vitamin D3 to the dipeptidyl peptidase‐4 inhibitor saxagliptin has the potential to protect β‐cell function in LADA patients: A 1‐year pilot study. Issue 5 (20th February 2020) - Zhang, Ziwei
Abstract: Aims: This trial was conducted to explore the protective effect on β‐cell function of adding vitamin D3 to DPP‐4 inhibitors to treat patients with latent autoimmune diabetes in adults (LADA). Methods: 60 LADA patients were randomized to group A ( n = 21) ‐ conventional therapy with metformin (1‐1.7 g/day) and/or insulin treatment; group B ( n = 20) ‐ saxagliptin (5 mg/day) plus conventional therapy; and group C ( n = 19) ‐ vitamin D3 (2000 IU/day) plus saxagliptin and conventional therapy for 12 months. Fasting and 2‐hour postprandial blood samples were collected to measure blood glucose, glycosylated hemoglobin and C‐peptide levels at baseline and after 3, 6 and 12 months of treatment. Results: During the 12 months of follow‐up, the levels of fasting C‐peptide (FCP), 2‐hour postprandial C‐peptide (PCP) and the C‐peptide index (CPI, serum C‐peptide‐to‐plasma glucose level ratio) were maintained in group C. In contrast to those in group A and group B, FCP levels decreased significantly in group B, and CPI levels declined significantly in group A during the 1‐year treatment ( P < .05). Additionally, the levels of GADA titers in group C significantly decreased compared with those at baseline ( P < .05), but no significant differences in GADA titers levels were detected in group A and group B. No significant differences were found among the three groups in the levels of FCP, PCP, the CPI or GADA titers. Conclusions: The data suggested that adding 2000 IU/day vitamin D3 to saxagliptin might preserve β‐cell function in patients with LADA.